A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients.
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Methylnaltrexone bromide (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Progenics Pharmaceuticals
- 01 Aug 2018 Removed Valeant Pharmaceuticals International and Salix Pharmaceuticals from this study as, this study was completed in Feb 2005 and as per RDI, in Feb 2011, Salix Pharmaceuticals (Valeant Pharmaceuticals International ( subsidiary of Valeant Pharmaceuticals International ) received the worldwide rights of the drug from Progenics.
- 09 Jun 2011 New trial record